Skip to main content
. Author manuscript; available in PMC: 2017 Dec 1.
Published in final edited form as: Transfus Apher Sci. 2016 Apr 25;54(2):181–190. doi: 10.1016/j.transci.2016.04.007

Fig. 2.

Fig. 2

TA-TMA pathogenesis. Transplant recipient’s genotype will determine subject at risk to develop TA-TMA under adequate stressors during HSCT like chemotherapy, radiation, infections, and medications. Complement system will be activated by the stressor in susceptible individuals leading to vascular endothelial injury due to activated terminal complement complex resulting in end organ injury.